Funding Organization: National Institutes of Health (NIH)
Total Funding Amount: Not specified
Duration: Up to 5 years
Primary Objective: To accelerate innovative drug and device therapies translation from discovery to early human studies for mental disorders.
Key Stakeholders: Academic institutions, industry partners, and research organizations.
Eligible organization types include higher education institutions, nonprofits, small businesses, local governments, and federal agencies.
Non-domestic (non-U.S.) entities are not eligible to apply.
Federal government agencies and U.S. territories are eligible.
U.S. based organizations are eligible; non-domestic components of U.S. organizations are not eligible.
Projects must focus on the discovery and development of pharmacologic and neuromodulatory tools for mental health disorders.
Partnerships between academia and industry are strongly encouraged.
Application budgets are not limited but must reflect the actual needs of the proposed project.
Application deadlines are set for January 25, 2025, with subsequent deadlines every six months until October 25, 2027.
Applicants may submit more than one application, provided each is scientifically distinct.
Applications must comply with the NIH application instructions and include a detailed research strategy.
Applications will be evaluated based on significance, innovation, approach, and investigator qualifications.
The grant encourages innovative, high-impact research and partnerships to enhance drug discovery.
Strong collaborations between academic and industry partners.
Clear demonstration of the project's relevance to mental health.